Mostrar el registro sencillo del ítem

dc.contributor.author
Monti Hughes, Andrea  
dc.contributor.author
Hu, Naonori  
dc.date.available
2024-06-11T10:09:58Z  
dc.date.issued
2023-08  
dc.identifier.citation
Monti Hughes, Andrea; Hu, Naonori; Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies; Multidisciplinary Digital Publishing Institute; Cancers; 15; 16; 8-2023; 1-30  
dc.identifier.issn
2072-6694  
dc.identifier.uri
http://hdl.handle.net/11336/237712  
dc.description.abstract
Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and StrategiesAndrea Monti Hughes 1 2, Naonori Hu 3 4Affiliations1Radiation Pathology Division, Department Radiobiology, National Atomic Energy Commission, San Martín, Buenos Aires B1650KNA, Argentina.2National Scientific and Technical Research Council, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina.3Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.4Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka 590-0494, Japan.AbstractBoron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed, in this review, those articles published between 2020 and 2023 reporting new boron compounds and strategies that were proved therapeutically useful in in vitro and/or in vivo radiobiological studies, a critical step for translation to a clinical setting. We also explored new pathologies that could potentially be treated with BNCT and newly developed theranostic boron agents. All these radiobiological advances intend to solve those limitations and questions that arise during patient treatment in the clinical field, with BNCT and other therapies. In this sense, active communication between clinicians, radiobiologists, and all disciplines will improve BNCT for cancer patients, in a cost- and time-effective way.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Multidisciplinary Digital Publishing Institute  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
BNCT;  
dc.subject
boron neutron capture therapy;  
dc.subject
new boron compounds;  
dc.subject
radiobiological studies;  
dc.subject
strategies;  
dc.subject
targeted therapy;  
dc.subject
theranostic compounds.  
dc.subject.classification
Otras Medicina Básica  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2024-06-07T15:21:31Z  
dc.journal.volume
15  
dc.journal.number
16  
dc.journal.pagination
1-30  
dc.journal.pais
Suiza  
dc.description.fil
Fil: Monti Hughes, Andrea. Comisión Nacional de Energía Atómica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Hu, Naonori. Osaka Medical and Pharmaceutical University; Japón. Kyoto University; Japón  
dc.journal.title
Cancers  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3390/cancers15164091